Piper Sandler raised the firm’s price target on Grail (GRAL) to $56 from $54 and keeps a Neutral rating on the shares. The firm notes the company delivered Q1 beat with 56,000 Galleri tests and $40.8M in revenue, but management opted to reiterate their 22%-32% full-year growth guide.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRAL:
- Daniel Brennan Reiterates Buy on Strong Galleri Momentum, Clinical Catalysts, and Raises Price Target to $69
- Grail reports Q1 EPS ($2.29), consensus ($1.96)
- Grail initiated with a Neutral at Mizuho
- Grail initiated with a Neutral at Piper Sandler
- Grail announces collaboration with Epic to bring Galleri test to EHR platforms